Combining HER2-targeted CAR T-cell therapy with immune checkpoint inhibitors, particularly PD-1 blockade, is an emerging strategy to enhance therapeutic efficacy in HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.